Exela Pharma Sciences – Recall of sodium bicarbonate injection

- On November 28, 2022, Exela Pharma Sciences announced an expansion to the voluntary consumer-level recall of sodium bicarbonate 8.4% injection to include an additional 14 lots because the product poses a potential safety concern with vial breakage and flying glass when pressurized while preparing the product for administration.
    - Clinical Services will send notifications to members and their prescribers potentially impacted by this recall.
    - The member letters advise members to not use the recalled product and contact their health care provider.
    - Other sodium bicarbonate injection products that are not being recalled are available for patients to use.
- This is an expansion to the recall that was announced in October 2022. Recalled product was distributed between October 26, 2021 through April 25, 2022. Refer to the press release for a list of recalled lots.
- Exela has received five reports of flying glass injuring skin, eye and/or other parts. There have been no reports of sterility failures.
- Sodium bicarbonate injection is indicated in the treatment of metabolic acidosis.
- Patients who have the recalled sodium bicarbonate injection should contact their physician or health care provider if they have experienced any problems that may be related to using the recalled products.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- Contact Exela by phone at **1-828-341-6118** or by email at **recall@exela.us** for more information.